On the Record · Biomarin Pharmaceutical

Biomarin Pharmaceutical acquisitions, on the record

The businesses Biomarin Pharmaceutical bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.

Deals its annual reports describe

Business	Deal	When	Value
KUVAN and PALYNZIQ global rights from Ares Trading S.A. (Merck Serono) Word for word“On October 1, 2015, the Company entered into an agreement with Ares Trading S.A. (Merck Serono) under which the Company acquired all global rights to KUVAN and PALYNZIQ from Merck Serono, with the exception of KUVAN in Japan.” 10-K for 2023	acquisition	October 1, 2015	—
all global rights to KUVAN and PALYNZIQ, with the exception of KUVAN in Japan Word for word“On October 1, 2015, the Company entered into an agreement with Ares Trading S.A. (Merck Serono) under which the Company acquired all global rights to KUVAN and PALYNZIQ from Merck Serono, with the exception of KUVAN in Japan.” 10-K for 2024	acquisition	October 1, 2015	—
Amicus Therapeutics, Inc. Word for word“In December 2025, we entered into a definitive agreement to acquire Amicus Therapeutics, Inc. (Amicus), a publicly traded, global, biotechnology company for $14.50 per share in an all-cash transaction for a total consideration of approximately $4.8 billion.” 10-K for 2025	agreed acquisition	December 2025	approximately $4.8 billion
Inozyme Pharma, Inc. Word for word“In July 2025, we completed the acquisition of Inozyme Pharma, Inc. (Inozyme), a publicly traded clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics.” 10-K for 2025	acquisition	July 2025	—

As filedReported in the company's financial data (XBRL), each linked to its filing
Fiscal year ended	Cash paid for acquisitions (net of cash acquired)
2016-12-31	$2.8 million
2017-12-31	$0
2018-12-31	$0

Deal filings since 2016

2026-09-30 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2026-08-31 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2026-08-18 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2026-04-27 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2026-04-27 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2026-02-12 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2025-12-19 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2025-05-16 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2024-09-04 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2023-12-20 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2022-02-14 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2021-06-02 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-05-14 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2018-10-23 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-11-28 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-08-11 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-04-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-12-19 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-12-02 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-08-11 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-01-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-01-07 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets

Read from Biomarin Pharmaceutical’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-26. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.